Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease

Stock Information for Hepion Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.